In the original article [1], there was a mistake in Figure 2A as published. The actin blot in our publication in Cancers (Figure 2A) had already been used in our published paper in Oncotarget in 2018. This is probably due to an error in our image saving. Note that this mistake does not change or alter the content and conclusions of our paper. The mistake indeed concerns control experiments, which were very easily reproduced. The corrected Figure 2A appears below.
In Figure 2B’s P53 panel, there are vertical splices between lanes 4/5 and 12/13. There are no apparent splices between these lanes in the other panels. This is because samples for every group (i.e., four conditions) were conducted on different membranes.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Krayem, M.; Sabbah, M.; Najem, A.; Wouters, A.; Lardon, F.; Simon, S.; Sales, F.; Journe, F.; Awada, A.; Ghanem, G.E.; et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).